{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:39:37Z","timestamp":1778243977561,"version":"3.51.4"},"reference-count":101,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher Education of the Russian Federation","award":["075-15-2024-638"],"award-info":[{"award-number":["075-15-2024-638"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The endogenous cannabinoid system (ECS) of the brain plays an important role in the molecular pathogenesis of Parkinson\u2019s disease (PD). It is involved in the formation of numerous clinical manifestations of the disease by regulating the level of endogenous cannabinoids and changing the activation of cannabinoid receptors (CBRs). Therefore, ECS modulation with new drugs specifically designed for this purpose may be a promising strategy in the treatment of PD. However, fine regulation of the ECS is quite a complex task due to the functional diversity of CBRs in the basal ganglia and other parts of the central nervous system. In this review, the effects of ECS modulators in various experimental models of PD in vivo and in vitro, as well as in patients with PD, are analyzed. Prospects for the development of new cannabinoid drugs for the treatment of motor and non-motor symptoms in PD are presented.<\/jats:p>","DOI":"10.3390\/ijms25158520","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T18:21:40Z","timestamp":1722882100000},"page":"8520","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic Application of Modulators of Endogenous Cannabinoid System in Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"25","author":[{"given":"Leonid G.","family":"Khaspekov","sequence":"first","affiliation":[{"name":"Brain Science Institute, Research Center of Neurology, Volokolamskoye Road, 80, 125367 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-6282","authenticated-orcid":false,"given":"Sergey N.","family":"Illarioshkin","sequence":"additional","affiliation":[{"name":"Brain Science Institute, Research Center of Neurology, Volokolamskoye Road, 80, 125367 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1192\/bjp.178.2.101","article-title":"Pharmacology and effects of cannabis: A brief review","volume":"178","author":"Ashton","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/agh110","article-title":"The endocannabinoid system: Physiology and pharmacology","volume":"40","author":"Bilbao","year":"2005","journal-title":"Alcohol Alcohol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.cell.2016.10.004","article-title":"Crystal structure of the human cannabinoid receptor CB(1)","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","article-title":"Crystal structure of the human cannabinoid receptor CB2","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Walsh, K.B., McKinney, A.E., and Holmes, A.E. (2021). Minor cannabinoids: Biosynthesis, molecular pharmacology and potential therapeutic uses. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.777804"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1476-5381.2010.00735.x","article-title":"The endocannabinoid system as a target for the treatment of neurodegenerative disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kibret, B.G., Canseco-Alba, A., Onaivi, E.S., and Engidawork, E. (2023). Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation. Front. Behav. Neurosci., 17.","DOI":"10.3389\/fnbeh.2023.1137957"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/FBP.0000000000000073","article-title":"Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs","volume":"25","author":"Batista","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s44158-024-00169-z","article-title":"Interplay between endocannabinoids and dopamine in the basal ganglia: Implications for pain in Parkinson\u2019s disease","volume":"4","author":"Mancini","year":"2024","journal-title":"J. Anesth. Analg. Crit. Care."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev.neuro.29.051605.112834","article-title":"Endocannabinoid-mediated synaptic plasticity in the CNS","volume":"29","author":"Chevaleyre","year":"2006","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., and Laezza, C. (2022). Cannabinoids: Therapeutic use in clinical practice. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063344"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural. Transm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/mds.29637","article-title":"What is the Parkinson pandemic?","volume":"38","author":"Albin","year":"2023","journal-title":"Mov. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3233\/JPD-239901","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2023 update","volume":"13","author":"McFarthinga","year":"2023","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JPD-225060","article-title":"Pharmacological treatment of tremor in Parkinson\u2019s disease revisited","volume":"13","author":"Pirkera","year":"2023","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson\u2019s disease","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Stanziano, M., Golfr\u00e8 Andreasi, N., Messina, G., Rinaldo, S., Palermo, S., Verri, M., Demichelis, G., Medina, J.P., Ghielmetti, F., and Bonvegna, S. (2022). Resting state functional connectivity signatures of MRgFUS Vim thalamotomy in Parkinson\u2019s disease: A preliminary study. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.786734"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2174\/1570159X21666221121094343","article-title":"Surgical advances in Parkinson\u2019s disease","volume":"22","author":"Hvingelby","year":"2024","journal-title":"Curr. Neuropharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101154","DOI":"10.1016\/j.ctcp.2020.101154","article-title":"Medical cannabis as an alternative therapeutics for Parkinsons\u2019 disease: Systematic review","volume":"39","author":"Bougea","year":"2020","journal-title":"Complement. Ther. Clin. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.parkreldis.2011.02.018","article-title":"Parkinson\u2019s disease: The non-motor issues","volume":"17","author":"Chaudhuri","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41582-023-00802-5","article-title":"The noradrenergic subtype of Parkinson disease: From animal models to clinical practice","volume":"19","author":"Chaudhuri","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease","volume":"24","author":"Barone","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.tpj.6500301","article-title":"Depression in Parkinson\u2019s disease is related a genetic polymorphism of the cannabinoid receptor gene (CNR1)","volume":"5","author":"Barrero","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.brainresbull.2019.01.016","article-title":"Cannabinoid receptor as a potential therapeutic target for Parkinson\u2019s disease","volume":"146","author":"Baul","year":"2019","journal-title":"Brain Res. Bull."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Han, Q.-W., Yuan, Y.-H., and Chen, N.-H. (2020). The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson\u2019s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 96.","DOI":"10.1016\/j.pnpbp.2019.109745"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1007\/s12035-020-02054-6","article-title":"Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson\u2019s and Alzheimer\u2019s diseases: A review","volume":"57","author":"Cooray","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-4522(01)00509-7","article-title":"Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain","volume":"109","author":"Hermann","year":"2002","journal-title":"Neuroscience"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbi.2016.06.010","article-title":"Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson\u2019s disease","volume":"57","author":"Celorrio","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1471-4159.2006.03880.x","article-title":"Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats","volume":"98","author":"Solinas","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.neurobiolaging.2014.05.021","article-title":"The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model","volume":"35","author":"Celorrio","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/jnr.23452","article-title":"Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage","volume":"92","author":"Gafni","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1476-5381.2011.01278.x","article-title":"Symptom-relieving and neuroprotective effects of the phytocannabinoid \u03949-THCV in animal models of Parkinson\u2019s disease","volume":"163","author":"Ramos","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11010-016-2733-y","article-title":"\u03b2-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease","volume":"418","author":"Ojha","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Burgaz, S., Garcia, C., Gomez-Canas, M., Munoz, E., and Fernandez-Ruiz, J. (2019). Development of an oral treatment with the PPAR-gamma-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson\u2019s disease. Molecules, 24.","DOI":"10.3390\/molecules24152702"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"107808","DOI":"10.1016\/j.neuropharm.2019.107808","article-title":"Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson\u2019s disease","volume":"163","author":"Ferrari","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13311-018-0603-x","article-title":"Cannabinoid CB1 and CB2 receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson\u2019s disease","volume":"15","author":"Navarrete","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.phrs.2016.04.004","article-title":"Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice","volume":"110","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2018.06.008","article-title":"Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson\u2019s disease","volume":"118","author":"Tozzi","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neuropharm.2015.10.021","article-title":"Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice","volume":"101","author":"Madeo","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/mds.25779","article-title":"Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects: \u03b1-SYN in the vermiform appendix","volume":"29","author":"Gray","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lamontagne-Proulx, J., Coulombe, K., Dahhani, F., C\u00f4t\u00e9, M., Guyaz, C., Tremblay, C., Di Marzo, V., Flamand, N., Calon, F., and Soulet, D. (2021). Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model. Nutrients, 13.","DOI":"10.3390\/nu13124218"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson\u2019s disease: Importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Ramos","year":"2007","journal-title":"Brain Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13167-020-00203-4","article-title":"Targeting the endocannabinoid system: A predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies","volume":"11","author":"Reddy","year":"2020","journal-title":"EPMA J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lacroix, C., Alleman-Brimault, I., Zalta, A., Rouby, F., Cass\u00e9-Perrot, C., Jouve, E., Attolini, L., Guilhaumou, R., Micallef, J., and Blin, O. (2022). What do we know about medical cannabis; in neurological disorders and what are the next steps?. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.883987"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Paes-Colli, Y., Aguiar, A.F.L., Isaac, A.R., Ferreira, B.K., Campos, R.M.P., Trindade, P.M.P., de Melo Reis, R.A., and Sampaio, L.S. (2022). Phytocannabinoids and cannabis-based products as alternative pharmacotherapy in neurodegenerative diseases: From hypothesis to clinical practice. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.917164"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wang, M., Liu, H., and Ma, Z. (2022). Roles of the cannabinoid system in the basal ganglia in Parkinson\u2019s disease. Front. Cell. Neurosci., 16.","DOI":"10.3389\/fncel.2022.832854"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4103\/1673-5374.382220","article-title":"Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: Preclinical models and clinical studies","volume":"4","author":"Duncan","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1007\/s11064-023-03899-8","article-title":"The effects of chronic marijuana administration on 6-OHDA-induced and memory impairment and hippocampal dopamine and cannabinoid receptors interaction in male rats","volume":"48","author":"Haghparast","year":"2023","journal-title":"Neurochem. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Morash, M.G., Nixon, J., Shimoda, L.M.N., Turner, H., Stokes, A.J., Small-Howard, A.L., and Ellis, L.D. (2022). Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson\u2019s disease. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.907579"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Prakash, S., and Carter, W.G. (2021). The neuroprotective effects of cannabis-derived phytocannabinoids and resveratrol in Parkinson\u2019s disease: A systematic literature review of pre-clinical studies. Brain Sci., 11.","DOI":"10.20944\/preprints202111.0050.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e100302","DOI":"10.1136\/bmjos-2022-100302","article-title":"Effects of cannabinoids in Parkinson\u2019s disease animal models: A systematic review and meta-analysis","volume":"6","author":"Urbi","year":"2022","journal-title":"BMJ Open Sci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Patricio, F., Morales-Andrade, A.A., Patricio-Mart\u00ednez, A., and Lim\u00f3n, I.D. (2020). Cannabidiol as a therapeutic target: Evidence of its neuroprotective and neuromodulatory function in Parkinson\u2019s disease. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.595635"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Giuliano, C., Francavilla, M., Ongari, G., Petese, A., Ghezzi, C., Rossini, N., Blandini, F., and Cerri, S. (2021). Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson\u2019s disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168920"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bhunia, S., Kolishetti, N., Arias, A.Y., Vashist, A., and Nair, M. (2022). Cannabidiol for neurodegenerative disorders: A comprehensive review. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.989717"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s42238-023-00186-9","article-title":"The therapeutic potential of purified cannabidiol","volume":"5","author":"Jensen","year":"2023","journal-title":"J. Cannabis Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8825358","DOI":"10.1155\/2023\/8825358","article-title":"Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: A comprehensive review","volume":"2023","author":"Singh","year":"2023","journal-title":"Behav. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.joim.2023.03.004","article-title":"Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications","volume":"21","author":"Tambe","year":"2023","journal-title":"J. Integr. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Burgaz, S., Garc\u00eda, C., G\u00f3mez-Ca\u00f1as, M., Rolland, A., Mu\u00f1oz, E., and Fern\u00e1ndez-Ruiz, J. (2021). Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in cell and murine models of Parkinson\u2019s disease. Molecules, 26.","DOI":"10.3390\/molecules26113245"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"104553","DOI":"10.1016\/j.fitote.2020.104553","article-title":"Cannabidiol exerts protective effects in an in vitro model of Parkinson\u2019s disease activating AKT\/mTOR pathway","volume":"143","author":"Gugliandolo","year":"2020","journal-title":"Fitoterapia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuroscience.2022.06.036","article-title":"Cannabidiol alleviates the damage to dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson\u2019s disease mice via regulating neuronal apoptosis and neuroinflammation","volume":"498","author":"Wang","year":"2022","journal-title":"Neuroscience"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10796","DOI":"10.18632\/aging.202951","article-title":"Potential role of cannabidiol in Parkinson\u2019s disease by targeting the WNT\/\u03b2-catenin pathway, oxidative stress and inflammation","volume":"13","author":"Vallee","year":"2021","journal-title":"Aging"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1042\/BST20120122","article-title":"The importance of Wnt signalling for neurodegeneration in Parkinson\u2019s disease","volume":"40","author":"Berwick","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"ref_66","first-page":"1525113","article-title":"Effects of cannabidiol on Parkinson\u2019s disease in a transgenic mouse model by gut-brain metabolic analysis","volume":"2022","author":"Zhao","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tiv.2015.11.004","article-title":"The neuroprotection of cannabidiol against MPP+-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson\u2019s disease","volume":"30","author":"Santos","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Javed, H., Azimullah, S., Haque, M.E., and Ojha, S.K. (2016). Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson\u2019s disease. Front. Neurosci., 10.","DOI":"10.3389\/fnins.2016.00321"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","article-title":"Cannabinoid CB2 receptor: A new target for controlling neural cell survival?","volume":"28","author":"Romero","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Yu, H., Liu, X., Chen, B., Vickstrom, C.R., Friedman, V., Kelly, T.J., Bai, X., Zhao, L., Hillard, C.J., and Liu, Q.-S. (2021). The neuroprotective effects of the CB2 agonist GW842166x in the 6-OHDA mouse model of Parkinson\u2019s disease. Cells, 10.","DOI":"10.3390\/cells10123548"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/biof.1936","article-title":"Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases","volume":"49","author":"Askari","year":"2023","journal-title":"Biofactors"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"114319","DOI":"10.1016\/j.expneurol.2023.114319","article-title":"The cannabinoid CB(1) receptor interacts with the angiotensin AT(2) receptor. Overexpression of AT(2)-CB(1) receptor heteromers in the striatum of 6-hydroxydopamine hemilesioned rats","volume":"362","author":"Lillo","year":"2023","journal-title":"Exp. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12640-022-00619-y","article-title":"Therapeutic molecular insights into the active engagement of cannabinoids in the therapy of Parkinson\u2019s disease: A novel and futuristic approach","volume":"41","author":"Jain","year":"2023","journal-title":"Neurotox. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease","volume":"19","author":"Fox","year":"2005","journal-title":"FASEB J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1007\/s00259-019-04445-x","article-title":"Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson\u2019s disease","volume":"11","author":"Ceccarini","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Basile, M.S., and Mazzon, E. (2022). The role of cannabinoid type 2 receptors in Parkinson\u2019s disease. Biomedicines., 10.","DOI":"10.3390\/biomedicines10112986"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/mds.23014","article-title":"Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson\u2019s disease patients","volume":"25","author":"Pisani","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/mds.23457","article-title":"Homeostatic changes of the endocannabinoid system in Parkinson\u2019s disease","volume":"26","author":"Pisani","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"van Laere, K., Casteels, C., Lunskens, S., Goffin, K., Grachev, I.D., Bormans, G., and Vandenberghe, W. (2012). Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo. Neurobiol. Aging, 33.","DOI":"10.1016\/j.neurobiolaging.2011.02.009"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/mds.29117","article-title":"Cannabinoid receptor type 1 in Parkinson\u2019s disease: A positron emission tomography study with [18F]FMPEP-d2","volume":"37","author":"Ajalin","year":"2022","journal-title":"Mov. Disord."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.4049\/jimmunol.1102435","article-title":"Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation","volume":"187","author":"Chung","year":"2011","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: An exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jcpt.12179","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: A case series","volume":"39","author":"Chagas","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","article-title":"Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: An open-label observational study","volume":"37","author":"Lotan","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ctim.2017.07.002","article-title":"Cannabis use in people with Parkinson\u2019s disease and multiple sclerosis: A web-based investigation","volume":"33","author":"Kindred","year":"2017","journal-title":"Complement. Ther. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/WNF.0000000000000246","article-title":"Medical cannabis in Parkinson disease: Real-life patients\u2019 experience","volume":"40","author":"Balash","year":"2017","journal-title":"Clin. Neuropharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ejp.942","article-title":"Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson\u2019s disease","volume":"21","author":"Shohet","year":"2017","journal-title":"Eur. J. Pain"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: A pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12640-019-00109-8","article-title":"Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson\u2019s disease and L-DOPA-induced dyskinesia","volume":"37","author":"Junior","year":"2020","journal-title":"Neurotox. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.25864","article-title":"Non-motor symptoms in Parkinson\u2019s disease are reduced by nabilone","volume":"88","author":"Peball","year":"2020","journal-title":"Ann. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/mdc3.13471","article-title":"Effects of nabilone on sleep outcomes in patients with Parkinson\u2019s disease: A post-hoc analysis of NMS-Nab study","volume":"9","author":"Peball","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/WNF.0000000000000550","article-title":"Medical cannabis in the treatment of Parkinson\u2019s disease","volume":"46","author":"Aladeen","year":"2023","journal-title":"Clin. Neuropharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/can.2023.0023","article-title":"Cannabinoids in treating Parkinson\u2019s disease symptoms: A systematic review of clinical studies","volume":"8","author":"Varshney","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JPD-202260","article-title":"Cannabis in Parkinson\u2019s disease: The patients\u2019 view","volume":"11","author":"Yenilmez","year":"2021","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3233\/JPD-212923","article-title":"Effects of cannabis in Parkinson\u2019s Disease: A systematic review and meta-analysis","volume":"12","author":"Urbi","year":"2022","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881119895536","article-title":"Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson\u2019s disease","volume":"34","author":"Tumas","year":"2020","journal-title":"J. Psychopharmacol"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13024-015-0012-0","article-title":"Promising cannabinoid-based therapies for Parkinson\u2019s disease: Motor symptoms to neuroprotection","volume":"10","author":"More","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"17562864211018561","DOI":"10.1177\/17562864211018561","article-title":"Cannabis and its derivatives for the use of motor symptoms in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"14","author":"Thanabalasingam","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8520\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:30:02Z","timestamp":1760110202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":101,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25158520"],"URL":"https:\/\/doi.org\/10.3390\/ijms25158520","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]}}}